StreetInsider.com News Articles

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Wed, 22 Jul 2026 16:05:00 -0400

NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2026.

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Wed, 22 Jul 2026 16:05:00 -0400

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Wed, 22 Jul 2026 16:05:00 -0400

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Wed, 22 Jul 2026 16:05:00 -0400

RBC Capital on Nuvation Bio Inc (NUVB): 'Ibtrozi Growth, Safu Optionality Create A Compelling Setup'

Wed, 22 Jul 2026 09:36:29 -0400

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $19.00 price target on Nuvation Bio Inc (NYSE: NUVB).

The analyst commented: "Takeaways From The Road: Ibtrozi Growth, Safu Optionality Create A Compelling Setup; We had the opportunity to take both NUVB's CFO and VP of Corporate Development on the road, where we touched on the company's near and longer term outlook. We noted significant excitement from the team on safu, where the strong recent data and newly announced trials should showcase the company's commitment to the asset that we believe could unlock over $3B in U.S. sales, and remains underappreciated

Nuvation Bio expands safusidenib trials after Phase 2 data update

Mon, 20 Jul 2026 08:00:38 -0400

Nuvation Bio Inc. (NYSE: NUVB) reported updated data from its Phase 2 J201 study of safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma, showing a confirmed overall response rate of 51.9% and a 36-month progression-free survival rate of 79.1% at a median follow-up of 38.8 months. The study enrolled 27 patients in Japan.

The company said responses deepened with additional follow-up, only one previously responding patient experienced subsequent disease progression, and no new safety signals were identified.

Based on these results, Nuvation Bio announced two new clinical studies for safusidenib. The first, a pivotal Phase 3 randomized, placebo-controlled study

Nuvation Bio expands safusidenib trials after Phase 2 data update

Mon, 20 Jul 2026 08:00:38 -0400

The company said responses deepened with additional follow-up, only one previously responding patient experienced subsequent disease progression, and no new safety signals were identified.

Based on these results, Nuvation Bio announced two new clinical studies for safusidenib. The first, a pivotal Phase 3 randomized, placebo-controlled study

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Mon, 20 Jul 2026 08:00:00 -0400

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up

New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S.

New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S.

NEW YORK, July 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Mon, 20 Jul 2026 08:00:00 -0400

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up

New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S.

New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S.

NEW YORK, July 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Mon, 20 Jul 2026 08:00:00 -0400

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up

New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S.

New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S.

NEW YORK, July 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Mon, 20 Jul 2026 08:00:00 -0400

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up

New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S.

New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S.

NEW YORK, July 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,

Form 4 Nuvation Bio Inc. For: Jul 15 Filed by: Sauvage Philippe

Fri, 17 Jul 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260717/26785390.html

Form 4 Nuvation Bio Inc. For: Jul 15 Filed by: Sauvage Philippe

Fri, 17 Jul 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260717/26785390.html

Nuvation Bio Inc (NUVB) PT Lowered to $19 at RBC Capital

Tue, 07 Jul 2026 08:00:20 -0400

RBC Capital analyst Leonid Timashev lowered the price target on Nuvation Bio Inc (NYSE: NUVB) to $19.00 (from $20.00) while maintaining a Outperform rating.

Nuvation Bio Inc (NUVB) PT Raised to $13 at Truist Securities

Tue, 07 Jul 2026 07:09:32 -0400

Truist Securities analyst Greg Renza raised the price target on Nuvation Bio Inc (NYSE: NUVB) to $13.00 (from $12.00) while maintaining a Buy rating.

Form 8-K Nuvation Bio Inc. For: Jun 30

Mon, 06 Jul 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260706/26736578.html

Form 8-K Nuvation Bio Inc. For: Jun 30

Mon, 06 Jul 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260706/26736578.html

Nuvation Bio raises $277.6M net in convertible notes after greenshoe

Mon, 06 Jul 2026 17:10:27 -0400

Nuvation Bio Inc. (NYSE: NUVB) announced that underwriters fully exercised their over-allotment option on its offering of 0.75% Convertible Senior Notes due 2032, bringing the total principal amount of notes sold to $287.5 million.

The greenshoe exercise added $37.5 million in aggregate principal to the offering. After underwriting discounts, commissions, and estimated offering expenses, Nuvation Bio estimates net proceeds of approximately $277.6 million.

On July 1, 2026, in connection with the greenshoe exercise, the company entered into additional capped call transactions at a cap price of $10.4580 per share, representing an 80% premium over the closing price of its Class A common

Nuvation Bio raises $277.6M net in convertible notes after greenshoe

Mon, 06 Jul 2026 17:10:27 -0400

Nuvation Bio raises $277.6M net in convertible notes after greenshoe

Mon, 06 Jul 2026 17:10:27 -0400

Nuvation Bio raises $277.6M net in convertible notes after greenshoe

Mon, 06 Jul 2026 17:10:27 -0400

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Mon, 06 Jul 2026 17:09:00 -0400

NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032 (the "Notes"). The aggregate principal amount of Notes sold in the offering was $287.5 million, inclusive of the $37.5 million aggregate principal amount of Notes issued pursuant

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Mon, 06 Jul 2026 17:09:00 -0400

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Mon, 06 Jul 2026 17:09:00 -0400

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Mon, 06 Jul 2026 17:09:00 -0400